Loading stock data…
ONC
$310.75-1.37 (-0.44%)
After Hours$310.75+0.00 (+0.00%)· Last close May 11
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BeOne Medicines AG in the Healthcare sector is trading at $310.75. The stock is currently 19% below its 52-week high of $385.22, remaining 3.2% below its 200-day moving average. Technical signals show neutral RSI of 49 and bullish MACD crossover, explaining why ONC maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$310.75
Potential Downside
86.4%
Whystock Fair Value$42.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Mean target$411.27+32.3%
Range$333.00 – $501.30
Fundamentals
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$34.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
126.48
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4.07%
Volume
Today's trading volume
322,546
Recent News
Earnings Beat: BeOne Medicines AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
BeOne Medicines AG ( NASDAQ:ONC ) defied analyst predictions to release its first-quarter results, which were ahead of...
BeOne Medicines Q1 Earnings Call Highlights
BeOne Medicines (NASDAQ:ONC) reported first-quarter 2026 results that management said reflected “strong execution across the business” and prompted the company to raise its full-year revenue outlook. Co-founder, Chairman and CEO John Oyler said the company entered 2026 with “tremendous momentum,” ci
Did FDA Fast-Track HER2 Regimen Just Shift BeOne Medicines' (ONC) Investment Narrative?
On 29 April 2026, BeOne Medicines announced that the FDA granted Priority Review to an sBLA for TEVIMBRA with ZIIHERA and chemotherapy, alongside Breakthrough Therapy Designation for ZIIHERA-based regimens in first-line treatment of unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, and esophageal adenocarcinoma. Backed by Phase 3 HERIZON-GEA-01 data showing extended overall and progression-free survival versus trastuzumab-based standard care, the...
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
BeOne Medicines price target lowered to $411 from $412 at Truist
Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm expect